Difference between revisions of "Aripiprazole LA-Flupenthixol LA"

From Psychiatrienet
Jump to: navigation, search
 
Line 1: Line 1:
 
{{Drugswitch  
 
{{Drugswitch  
 
| from = Aripiprazole LA
 
| from = Aripiprazole LA
| to = Fluphenazine LA
+
| to = Flupenthixol LA
 
| stop = {{Lastinjection}}
 
| stop = {{Lastinjection}}
 
| start = {{StartDepot2}}
 
| start = {{StartDepot2}}

Latest revision as of 13:42, 20 March 2015

Aripiprazole
long acting
Type Antipsychotic
Group Atypical AP
Other use moodstabilizer
links
Medscape Aripiprazole
EMEA abilify
PubChem 60975
PubMed Aripiprazole
Kompas (Dutch) Aripiprazole
Wikipedia Aripiprazole
Flupenthixol
long acting
Type Antipsychotic
Group Thioxanthenes
links
Medscape Flupenthixol
PubChem 17012
PubMed Flupenthixol
Kompas (Dutch) Flupenthixol
Wikipedia Flupenthixol

Switch medication from Aripiprazole LA to Flupenthixol LA.[1] [2]

Nietinrijdenbord.png Stop Aripiprazole LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Flupenthixol LA
  • Start depot according to general dosing advice on the day you normally would have injected the former depot.
  • Testing for acceptance and possible allergic reactions in a low dose can be carried out earlier.
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[3]
  • More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. [4]
    StopDepotStartArip.jpg
Nietinrijdenbord.png — Aripiprazole LA
Eenrichtingbord.png — Flupenthixol LA


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
  4. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf SPC of the European Medicines Agency on aripiprazole depot
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.